Medicare Enrolled
Dr. Susmita Sakruti, M.D
Medical Oncology · Denison, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Sakruti from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sakruti? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sakruti
Dr. Susmita Sakruti is a medical oncology in Denison, TX, with 15 years in practice. Based on federal Medicare data, Dr. Sakruti performed 129,293 Medicare services across 5,002 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sakruti received a total of $9,607 from 69 pharmaceutical and/or device companies across 452 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sakruti is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years in practice▲ Top 5% volume in TX$ $9,607 industry payments
Medicare Practice Summary
Medicare Utilization ↗129,293
Medicare services
Top 5% in TX for medical oncology
5,002
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~8,620 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 28,560 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 16,100 | $43 | $137 |
| Oxaliplatin chemotherapy injection | 12,100 | $0 | $33 |
| Darbepoetin injection (Aranesp) for anemia | 10,050 | $2 | $20 |
| Iron sucrose injection (Venofer) | 9,600 | $0 | $2 |
| Paclitaxel chemotherapy injection | 9,386 | $0 | $8 |
| Contrast dye for imaging (iodine-based) | 6,950 | $0 | $3 |
| Nivolumab injection (Opdivo) | 6,100 | $24 | $77 |
| Denosumab injection (Prolia/Xgeva) | 3,900 | $19 | $67 |
| Anti-nausea injection (fosaprepitant) | 3,450 | $0 | $5 |
| Injection, docetaxel, 1 mg | 2,048 | $1 | $66 |
| Dexamethasone injection (steroid) | 2,020 | $0 | $1 |
| Complete blood count (CBC) with differential | 1,760 | $8 | $36 |
| Blood draw (venipuncture) | 1,614 | $8 | $20 |
| Immune globulin infusion (Octagam) | 1,590 | $34 | $235 |
| Comprehensive metabolic blood panel | 1,532 | $10 | $64 |
| Injection, bortezomib, 0.1 mg | 1,330 | $3 | $116 |
| Injection, granisetron hydrochloride, 100 mcg | 930 | $0 | $24 |
| Injection, leucovorin calcium, per 50 mg | 830 | $3 | $25 |
| Office visit, established patient (30-39 min) | 771 | $96 | $368 |
| Injection, fluorouracil, 500 mg | 730 | $2 | $13 |
| Anti-nausea injection (Aloxi/palonosetron) | 610 | $1 | $114 |
| Office visit, established patient (20-29 min) | 469 | $59 | $250 |
| Injection, carboplatin, 50 mg | 434 | $2 | $300 |
| Injection, etoposide, 10 mg | 410 | $1 | $13 |
| Administration of chemotherapy into vein, 1 hour or less | 394 | $99 | $707 |
| Injection, irinotecan, 20 mg | 359 | $2 | $210 |
| Injection of additional new drug or substance into vein | 296 | $12 | $108 |
| Ferritin level test (iron stores) | 292 | $13 | $60 |
| Iron level test | 288 | $6 | $27 |
| Iron binding capacity test | 288 | $8 | $35 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 268 | $3 | $373 |
| Lactate dehydrogenase (enzyme) level | 236 | $6 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 222 | $22 | $157 |
| Injection, zoledronic acid, 1 mg | 202 | $6 | $431 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 178 | $48 | $313 |
| Administration of additional new drug or substance into vein, 1 hour or less | 162 | $49 | $344 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 156 | $55 | $211 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 133 | $278 | $2,762 |
| Drug injection, under skin or into muscle | 132 | $11 | $96 |
| Administration of chemotherapy into vein, each additional hour | 128 | $22 | $161 |
| PSA test (prostate cancer screening) | 125 | $18 | $94 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 104 | $134 | $3,675 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 100 | $327 | $1,722 |
| Carcinoembryonic antigen (cea) protein level | 88 | $18 | $99 |
| Injection, diphenhydramine hcl, up to 50 mg | 83 | $1 | $7 |
| Ct scan of chest with contrast | 80 | $53 | $821 |
| Magnesium level test | 78 | $7 | $29 |
| Microscopic examination for white blood cells with manual cell count | 77 | $4 | $22 |
| Complete blood count (CBC), automated | 77 | $6 | $34 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 73 | $125 | $500 |
| Irrigation of implanted venous access drug delivery device | 70 | $17 | $114 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 68 | $90 | $657 |
| Injection, magnesium sulfate, per 500 mg | 66 | $1 | $6 |
| Initial hospital admission, moderate complexity | 65 | $102 | $470 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 64 | $15 | $94 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 63 | $1,136 | $4,802 |
| Office visit, established patient, complex (40-54 min) | 63 | $135 | $496 |
| CT scan of abdomen and pelvis with contrast | 59 | $173 | $1,067 |
| Hospital follow-up visit, moderate complexity | 59 | $62 | $247 |
| Unclassified drugs | 58 | $1 | $8 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 57 | $20 | $128 |
| Administration of additional new drug or substance into vein using push technique | 57 | $43 | $289 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 54 | $20 | $128 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 53 | $26 | $145 |
| New patient office visit (45-59 min) | 45 | $125 | $565 |
| Infusion, normal saline solution , 1000 cc | 44 | $2 | $19 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 44 | $72 | $70 |
| Uric acid level test | 41 | $4 | $25 |
| Blood creatinine level | 37 | $5 | $31 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 35 | $64 | $348 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 33 | $182 | $700 |
| New patient office visit (30-44 min) | 30 | $72 | $372 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 29 | $16 | $100 |
| Drawing of blood for a medical problem | 26 | $66 | $264 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | 25 | $181 | $700 |
| Manual urinalysis test with examination using microscope, non-automated | 24 | $4 | $26 |
| CT scan of chest, without contrast | 23 | $35 | $686 |
| Red blood count automated, with additional calculations | 20 | $5 | $26 |
| Infusion into a vein for hydration, 31-60 minutes | 18 | $22 | $256 |
| Ct scan of abdomen and pelvis without contrast | 16 | $75 | $560 |
| Infusion into a vein for hydration, each additional hour | 16 | $9 | $75 |
| Ct scan of soft tissue of neck with contrast | 14 | $66 | $658 |
| Basic metabolic blood panel | 12 | $8 | $49 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $66 | $231 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
23.8% high complexity
69.2% medium
6.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,607
Total received (2018-2024)
Avg $1,372/year across 7 years
Top 38% in TX for medical oncology
69
Companies
452
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,687 (80.0%)
Other
Charitable contributions, space rental, and other categories
$1,239 (12.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$681 (7.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$535
2023$430
2022$1,587
2021$3,761
2020$2,049
2019$1,120
2018$125
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,357
E.R. Squibb & Sons, L.L.C.
$661
Incyte Corporation
$549
PFIZER INC.
$517
Amgen Inc.
$447
Astellas Pharma US Inc
$445
Celgene Corporation
$367
Janssen Biotech, Inc.
$273
GlaxoSmithKline, LLC.
$267
Pharmacyclics LLC, An AbbVie Company
$218
Daiichi Sankyo Inc.
$218
AstraZeneca Pharmaceuticals LP
$205
Lilly USA, LLC
$196
Merck Sharp & Dohme Corporation
$192
GENZYME CORPORATION
$180
Taiho Oncology, Inc.
$177
NOVARTIS PHARMACEUTICALS CORPORATION
$167
Dova Pharmaceuticals
$164
Seagen Inc.
$162
Bayer HealthCare Pharmaceuticals Inc.
$153
ARRAY BIOPHARMA INC
$138
Global Blood Therapeutics, Inc.
$124
Exelixis Inc.
$113
Puma Biotechnology, Inc.
$113
Karyopharm Therapeutics Inc.
$112
EMD Serono, Inc.
$112
Foundation Medicine, Inc.
$110
SANOFI-AVENTIS U.S. LLC
$100
Regeneron Healthcare Solutions, Inc.
$100
Pharmacyclics LLC, an AbbVie Company
$96
Eisai Inc.
$88
Secura Bio, Inc.
$80
Blueprint Medicines Corporation
$78
EUSA Pharma (US) LLC
$77
Verastem, Inc.
$68
Epizyme, Inc.,
$65
Merck Sharp & Dohme LLC
$65
Genentech USA, Inc.
$57
Janssen Pharmaceuticals, Inc
$53
Gilead Sciences, Inc.
$52
Takeda Pharmaceuticals U.S.A., Inc.
$51
PUMA BIOTECHNOLOGY, INC.
$50
Alexion Pharmaceuticals, Inc.
$48
Clovis Oncology, Inc.
$47
Deciphera Pharmaceuticals Inc.
$46
JAZZ PHARMACEUTICALS INC.
$45
Boehringer Ingelheim Pharmaceuticals, Inc.
$44
Tempus AI, Inc
$43
GE HealthCare
$41
ABBVIE INC.
$39
Medtronic, Inc.
$32
BeiGene USA, Inc.
$31
TerSera Therapeutics LLC
$31
EISAI INC.
$29
Adaptive Biotechnologies Corporation
$27
MorphoSys, US Inc.
$24
Rigel Pharmaceuticals, Inc.
$24
Array BioPharma Inc.
$23
Jazz Pharmaceuticals Inc.
$23
Seattle Genetics, Inc.
$23
Ipsen Biopharmaceuticals, Inc
$23
Partner Therapeutics, Inc.
$23
SOBI, INC
$21
G1 Therapeutics, Inc.
$21
Progenics Pharmaceuticals, Inc.
$21
Servier Pharmaceuticals LLC
$16
Emmaus Medical, Inc.
$16
Stemline Therapeutics Inc.
$15
Advanced Accelerator Applications
$11
Top 3 companies account for 26.7% of total payments
Associated products mentioned in payments ›
ADCETRIS · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Braftovi · CABOMETYX · CALQUENCE · COSELA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · EMPLICITI · EPKINLY · ERBITUX · ERLEADA · EXKIVITY · Endari · Enhertu · Erleada · FARYDAK · FOUNDATIONONE · FRUZAQLA · Farydak · GAVRETO · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · INREBIC · Imbruvica · Inrebic · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · MEKINIST · MONJUVI · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OJJAARA · ONCASPAR · ONUREG · OPDIVO · OSTEOCOOL RF ABLATION SYSTEM · OXBRYTA · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PROMACTA · PYLARIFY · Pomalyst · QINLOCK · REBLOZYL · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TUKYSA · Tavalisse · Trodelvy · Ultomiris · VERZENIO · Vectibix · Venclexta · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xospata · Xtandi · ZEJULA · ZEPZELCA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (80%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $7 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
2.9
County median income
$70,455
Nearest hospital
TEXOMA MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Sakruti is a mixed practice specialist, with above-average Medicare volume (top 5% in TX), and low-engagement industry engagement, with 15 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Sakruti experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Sakruti performed 28,560 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sakruti receive payments from pharmaceutical companies?
Yes. Dr. Sakruti received a total of $9,607 from 69 companies across 452 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sakruti's costs compare to other medical oncologys in Denison?
Dr. Sakruti's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sakruti) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Denison
Browse medical oncologys in Denison ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology